Development of early warning features and guidance in the area of pricing through the EURIPID database

ended

"Seven national bodies, namely NEAK (HU), GÖG (AT), RIZIV (BE), NCPRMP (BG), AOTMiT (PL), INFARMED (PT) and JAZMP (SI) have teamed up to offer guidance in the area of pricing through the EURIPID database and develop early warning features, based on competition cases. Six of the applicants are current members of the EURIPID Collaboration (www.euripid.eu), whereby the project lead NEAK and GÖG work together already since 2010. EURIPID provides information on medicines and their prices in a standardised, continuously updated format. As of May 2022, information was available for 29 countries, thereof 26 partners of the Collaboration. This undertaking will provide analysis and generate evidence, e.g. on certain commercial practices like strategic price increases (in WP 4), will offer capacity building and training including a proposal to update the EURIPID Technical Guidance Document on External Price Referencing of Medicinal Products (in WP 5) and will adapt the EURIPID database and website interface based on this learnings (WP 3). The existing EURIPID database will be completed with functionalities to enable early warning for the national competent authorities in charge of pricing and reimbursement of medicinal products in case of excessing pricing. Based on the new functionalities of the EURIPID website certain commercial practices of pharmaceutical companies will be addressed and quick check format analyses, so called policy briefs will be prepared. The analytical activities will include the monitoring of strategic sequencing of price increases or of threats to delist products. Finally, with hosting or attending a number of webinars/workshops the cooperation between authorities to address the challenges due to certain commercial practices will be strenghtend on the one hand, and on the other hand the dialogue on pharmaceutical pricing topics with stakeholders of the pharmaceutical sector will be continued in the established ""Stakeholder Dialogue Format""."